• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

    6/24/22 9:09:00 AM ET
    $ETON
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETON alert in real time by email

    Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")) today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based-Eton Pharmaceuticals, Inc. (NASDAQ:ETON).

    The portfolio includes the Biorphen® (phenylephrine hydrocholoride) Injection and Rezipres® (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved ANDA for Cysteine Hydrochloride for the U.S. One strength each of Biorphen® and Rezipres® are currently commercially available in the U.S. The acquisition will complement Dr. Reddy's U.S. institutional business with limited competition injectable products.

    Under the terms of the agreement, Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million. The acquisition supports Dr. Reddy's efforts to accelerate and expand affordable medications for patients.

    "Long before the COVID-19 pandemic, there have been concerns about access to some critical care products for hospitals and health systems. This acquisition provides our North America organization with a foundational footprint to help address products that are not always readily available for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's. "For these and many other reasons, I believe we are well-positioned to integrate the portfolio and grow the business."

    The value of total addressable market for these products in the U.S. is approximately $174 million for the calendar year ending in April 2022 according to IQVIA.

    *IQVIA Retail and Non-Retail MAT April 2022

    RDY-0622-419

    About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

    Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220624005239/en/

    Get the next $ETON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ETON
    $RDY

    CompanyDatePrice TargetRatingAnalyst
    Dr. Reddy's Laboratories Ltd
    $RDY
    6/5/2025$16.89Hold → Buy
    HSBC Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    1/10/2025$21.00Buy
    B. Riley Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    Dr. Reddy's Laboratories Ltd
    $RDY
    12/19/2024Buy → Neutral
    Nomura
    Eton Pharmaceuticals Inc.
    $ETON
    9/4/2024$9.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    5/6/2024$8.00Buy
    Craig Hallum
    Dr. Reddy's Laboratories Ltd
    $RDY
    1/11/2024Buy → Underperform
    Jefferies
    More analyst ratings

    $ETON
    $RDY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/16/25 4:56:08 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Brynjelsen Sean sold $3,592,611 worth of shares (210,000 units at $17.11), decreasing direct ownership by 7% to 2,873,513 units (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/5/25 5:15:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETON
    $RDY
    Financials

    Live finance-specific insights

    See more
    • Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

      Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of product candidate ET-700Announced positive pivotal clinical study results for ET-600 and submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration

      5/13/25 4:01:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only)        Click Here Webcast:                          Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can

      5/1/25 4:30:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETON
    $RDY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/25/24 4:05:24 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/8/24 6:34:32 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETON
    $RDY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

      DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution. "Eton's addition to the Russell 2000 and Russell 3000 Indexes is a significant milestone and recognizes the tremendous shareholder value we've generated over the past twelve months. We're proud to be part of these important market performance benchmarks and

      6/27/25 6:50:00 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

      Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines

      6/5/25 7:00:00 AM ET
      $ALVO
      $RDY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

      HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, world

      6/5/25 2:55:00 AM ET
      $ALVO
      $RDY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations